Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 10/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.36 |
| ▸ | FPR3 | P25089 | 3/20 | 0.35 |
| ▸ | FPR2 | P25090 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27809719 | 0.88 | BACE1 (0.35) | BACE1AAK1GHSR | |
| SCHEMBL31730428 | 0.85 | NR1H2 (0.45) | BACE1AAK1GHSRGAA | |
| SCHEMBL31730656 | 0.83 | BACE1 (0.41) | BACE1AAK1NPC1RECQLRAB9A | |
| SCHEMBL23223760 | 0.82 | GHSR (0.45) | BACE1GHSR | |
| SCHEMBL18088760 | 0.82 | GHSR (0.45) | BACE1GHSR | |
| SCHEMBL17040414 | 0.80 | AAK1 (0.38) | BACE1AAK1SMN1; SMN2GHSRGAA | |
| SCHEMBL31388812 | 0.78 | BACE1 (0.38) | BACE1AAK1NPC1RECQLRAB9A | |
| SCHEMBL31730593 | 0.77 | OPRD1 (0.36) | BACE1AAK1GHSR | |
| SCHEMBL17988102 | 0.76 | KDM1A (0.44) | BACE1AAK1NPC1RECQLRAB9A | |
| SCHEMBL26401066 | 0.76 | GHSR (0.46) | BACE1AAK1NPC1RECQLRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353817-A1 | INTERLUKIN-17A INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-11-20 | — | — | US | disclosed |
| EP-3107900-B1 | 5-BENZYLISOQUINOLEINE DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | SERVIER LAB (FR) | 2017-11-15 | — | — | EP | disclosed |
| US-9809553-B2 | Isoquinoline compounds, a process for their preparation, and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2017-11-07 | — | — | US | disclosed |
| US-9809553-B2 | Isoquinoline compounds, a process for their preparation, and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2017-11-07 | — | — | US | disclosed |
| US-20170137385-A1 | ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2017-05-18 | — | — | US | disclosed |
| US-20170137385-A1 | ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2017-05-18 | — | — | US | disclosed |
| WO-2015124877-A1 | DERIVATIVES OF 5-BENZYLISOQUINOLINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | LES LABORATOIRES SERVIER (FR) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353817-A1 | INTERLUKIN-17A INHIBITORS AND USES THEREOF | IL17A, IL15, IL23R | BACE1 751/4885AAK1 2477/4885NPC1 2168/4885 |
| US-20170137385-A1 | ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MYLK, MYLK2, MYLK3 | BACE1 3771/4885AAK1 2041/4885NPC1 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.